Deep-dive pillar hubs covering the major peptide classes we track. Each hub pulls together every article, FAQ, and tool for that topic.
GLP-1 receptor agonists mimic the gut hormone glucagon-like peptide-1 to improve glycemic control and drive weight loss. This hub pulls together our complete research coverage of semaglutide, tirzepatide, retatrutide and…
Semaglutide is a long-acting GLP-1 receptor agonist marketed as Ozempic (type 2 diabetes) and Wegovy (chronic weight management). This hub covers the STEP Phase 3 program, dosing titration, reconstitution math, side-effe…
Tirzepatide is a dual GIP and GLP-1 receptor agonist marketed as Mounjaro (T2D) and Zepbound (weight management). This hub consolidates SURMOUNT Phase 3 data, dosing math, injection logistics, side-effect management and …
Retatrutide is Eli Lilly's investigational triple agonist, targeting GLP-1, GIP and glucagon receptors. Phase 3 TRIUMPH-1 data (Oct 2026) reported ~30% body-weight loss at 12 mg — the largest observed with any obesity ph…
BPC-157 is a pentadecapeptide derived from a gastric protein, studied for tissue repair, tendon healing, and gut-barrier effects. This hub covers mechanism, oral vs injection routes, dosing protocols, and the comparison …
Growth hormone secretagogues — including ipamorelin, CJC-1295, hexarelin, tesamorelin and sermorelin — stimulate pulsatile GH release from the pituitary. This hub covers mechanism (GHRH vs GHRP), blend protocols, and res…
Peptide-based obesity pharmacotherapy has transformed metabolic medicine. This hub spans the full landscape — GLP-1 monotherapy, dual and triple agonists, amylin co-agonists (cagrilintide), oral options, and the practica…